Ly, Neang S. http://orcid.org/0000-0002-5571-0347
Li, Jing
Faggioni, Raffaella
Roskos, Lorin K.
Brose, Marcia S.
Funding for this research was provided by:
Exelixis, Inc.
Article History
Accepted: 8 January 2023
First Online: 4 March 2023
Declarations
:
: For the cabozantinib clinical studies included in these analyses, the study protocols were approved by the institutional review board or ethics committee at each center.
: Informed consent was obtained from all individual participants included in the study.
: Not applicable.
: The datasets generated during and/or analyzed during the current study are not publicly available due to confidentiality and lack of patient consent for data sharing but may be available from the corresponding author on reasonable request.
: Not applicable.
: This study was funded by Exelixis, Inc., Alameda, CA, USA (no grant number).
: Neang S. Ly, Jing Li, Raffaella Faggioni, and Lorin K. Roskos are employees and stockholders of Exelixis. Marcia S. Brose received honoraria from Bayer, Eisai, and Lilly, research funding from Bayer (Inst), Blueprint Medicines (Inst), Eisai (Inst), Exelixis (Inst), Lilly (Inst), and Loxo (Inst), and had a consulting or advisory role with Bayer, Blueprint Medicines, Eisai, Exelixis, Lilly, and Loxo.